Ev 302 Keynote A39 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ev 302 keynote a39 trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ev 302 Keynote A39 Trial Today - Breaking & Trending Today

EV-302 Regimen Bests Chemo in Advanced Urothelial Cancer

Findings from the EV-302 trial presented at the 2023 ESMO Congress revealed that the combination of enfortumab vedotin and pembrolizumab may become the preferred frontline standard of care for patients with locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility. ....

City Of , United Kingdom , Thomasb Powles , Barts Cancer Centre At St Bartholomew Hospital , Barts Cancer Centre , Frontline Treatment , Ev 302 , Urothelial Cancer , Ev 302 Keynote A39 Trial , Enfortumab Vedotin And Pembrolizumab ,